Whole‐body dose equivalent including neutrons is similar for 6 MV and 15 MV IMRT, VMAT, and 3D conformal radiotherapy by Hauri, Pascal & Schneider, Uwe
Zurich Open Repository and
Archive
University of Zurich
Main Library
Strickhofstrasse 39
CH-8057 Zurich
www.zora.uzh.ch
Year: 2019
Whole‐body dose equivalent including neutrons is similar for 6 MV and 15
MV IMRT, VMAT, and 3D conformal radiotherapy
Hauri, Pascal ; Schneider, Uwe
Abstract: Purpose This study investigates the difference in whole‐body dose equivalent between 6 and
15 MV image‐guided radiotherapy (IGRT) for the treatment of a rhabdomyosarcoma in the prostate.
Methods A previously developed model for stray radiation of the primary beam was improved and used
to calculate the photon dose and photon energy in the out‐of‐field region for a radiotherapy patient. The
dose calculated by the treatment planning system was fused with the model‐calculated out‐of‐field dose,
resulting in a whole‐body photon dose distribution. The peripheral neutron dose equivalent was calcu-
lated using an analytical model from the literature. A daily cone beam CT dose was added to the neutron
and photon dose equivalents. The calculated 3D dose distributions were compared to independent mea-
surements conducted with thermoluminescence dosimeters and an anthropomorphic phantom. The dose
contributions from the IGRT treatments of three different techniques applied with two nominal X‐ray
energies were compared using dose equivalent volume histograms (DEVHs). Results The calculated and
measured out‐of‐field whole‐body dose equivalents for the IGRT treatments agreed within (9 ± 10) %
(mean and type A SD). The neutron dose equivalent was a minor contribution to the total out‐of‐field
dose up to 50 cm from the isocenter. Further from the isocenter, head leakage was dominating inside
the patient body, whereas the neutron dose equivalent contribution was important close to the surface.
There were small differences between the whole‐body DEVHs of the 6 and 15 MV treatments applied
with the same technique, although the single scatter contributions showed large differences. Independent
of the beam energy, the out‐of‐field dose of the volumetric‐modulated arc therapy (VMAT) treatment
was significantly lower than the dynamic intensity‐modulated radiation therapy (IMRT) treatment. Con-
clusion The calculated whole‐body dose helped to understand the importance of the dose contributions
in different areas of the patient. Regarding radiation protection of the patient for IGRT treatments, the
choice of beam energy is not important, whereas the treatment technique has a large influence on the
out‐of‐field dose. If the patient is treated with intensity‐modulated beams, VMAT should be used instead
of dynamic IMRT in terms of radiation protection of the patient. In general, the developed models for
photon and neutron dose equivalent calculation can be used for any patient geometry, tumor location,
and linear accelerator.
DOI: https://doi.org/10.1002/acm2.12543
Posted at the Zurich Open Repository and Archive, University of Zurich
ZORA URL: https://doi.org/10.5167/uzh-181399
Journal Article
Published Version
 
 
The following work is licensed under a Creative Commons: Attribution 4.0 International (CC BY 4.0)
License.
Originally published at:
Hauri, Pascal; Schneider, Uwe (2019). Whole‐body dose equivalent including neutrons is similar for 6
MV and 15 MV IMRT, VMAT, and 3D conformal radiotherapy. Journal of Applied Clinical Medical
Physics, 20(3):56-70.
DOI: https://doi.org/10.1002/acm2.12543
2
R AD I A T I ON ONCO LOG Y PH Y S I C S
Whole‐body dose equivalent including neutrons is similar for
6 MV and 15 MV IMRT, VMAT, and 3D conformal
radiotherapy
Pascal Hauri1,2 | Uwe Schneider1,2
1Department of Physics, University of
Zurich, Zurich, Switzerland
2Radiotherapy Hirslanden, Hirslanden
Medical Center, Aarau, Switzerland
Author to whom correspondence should be
addressed. Pascal Hauri
E-mail: pascal.hauri2@uzh.ch
Funding information
Swiss Cancer League, Grant/Award Number:
KFS-3249-08-2013
Abstract
Purpose: This study investigates the difference in whole‐body dose equivalent
between 6 and 15 MV image‐guided radiotherapy (IGRT) for the treatment of a
rhabdomyosarcoma in the prostate.
Methods: A previously developed model for stray radiation of the primary beam
was improved and used to calculate the photon dose and photon energy in the out‐
of‐ﬁeld region for a radiotherapy patient. The dose calculated by the treatment plan-
ning system was fused with the model‐calculated out‐of‐ﬁeld dose, resulting in a
whole‐body photon dose distribution. The peripheral neutron dose equivalent was
calculated using an analytical model from the literature. A daily cone beam CT dose
was added to the neutron and photon dose equivalents. The calculated 3D dose dis-
tributions were compared to independent measurements conducted with thermolu-
minescence dosimeters and an anthropomorphic phantom. The dose contributions
from the IGRT treatments of three different techniques applied with two nominal
X‐ray energies were compared using dose equivalent volume histograms (DEVHs).
Results: The calculated and measured out‐of‐ﬁeld whole‐body dose equivalents for
the IGRT treatments agreed within (9 ± 10) % (mean and type A SD). The neutron dose
equivalent was a minor contribution to the total out‐of‐ﬁeld dose up to 50 cm from the
isocenter. Further from the isocenter, head leakage was dominating inside the patient
body, whereas the neutron dose equivalent contribution was important close to the
surface. There were small differences between the whole‐body DEVHs of the 6 and
15 MV treatments applied with the same technique, although the single scatter contri-
butions showed large differences. Independent of the beam energy, the out‐of‐ﬁeld
dose of the volumetric‐modulated arc therapy (VMAT) treatment was signiﬁcantly
lower than the dynamic intensity‐modulated radiation therapy (IMRT) treatment.
Conclusion: The calculated whole‐body dose helped to understand the importance
of the dose contributions in different areas of the patient. Regarding radiation pro-
tection of the patient for IGRT treatments, the choice of beam energy is not impor-
tant, whereas the treatment technique has a large inﬂuence on the out‐of‐ﬁeld dose.
If the patient is treated with intensity‐modulated beams, VMAT should be used
instead of dynamic IMRT in terms of radiation protection of the patient. In general,
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the developed models for photon and neutron dose equivalent calculation can be
used for any patient geometry, tumor location, and linear accelerator.
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1 | INTRODUCTION
Around 10% of long‐term cancer survivors develop a second tumor.
Ten percent of these second tumors are induced by the radiation
treatment the patient received.1 Most second cancers occur at the
peripheral region where the dose is greater than 3.0 Gy.1 However,
Diallo et al.2 identiﬁed a peak frequency in second malignant neo-
plasm (including spontaneous cancers) for volumes that received a
dose smaller than 2.5 Gy. In external radiation beam therapy, the
treated volume receives a high dose while the remaining body is
exposed to an unwanted low dose of radiation. Usually, the dose is
calculated around the target volume and the out‐of‐ﬁeld dose is not
accurately considered, if at all.3 Therefore, whole‐body dose distribu-
tions are needed for accurate cancer risk estimates and for optimiz-
ing treatment plans by minimizing the cancer risk.
Another motivation for whole‐body dose calculation is the radia-
tion protection of the fetus. Negative effects for a fetus can be sub-
stantially minimized if the dose to it is reduced to 100 mGy.4
However, practical models to estimate the fetal exposure for inten-
sity‐modulated treatments of pregnant patients do not yet exist.1
Takam et al.5 presented the current status of out‐of‐ﬁeld neutron
and photon leakage dose in radiotherapy and the associated risk for
the patient. Most of their results were based on patient treatments
which occurred decades ago. Therefore, studies including novel
treatment machines and techniques are urgently needed.5
For the same technique applied with different nominal X‐ray
energies, the target coverage, conformity, and homogeneity of the
treatments are similar.6 The choice of nominal X‐ray energy should
be based on normal tissue complication probability and on radiation
protection issues of the patient. Many studies investigated the dif-
ference in the peripheral dose between high (≥10 MV) and low nomi-
nal X‐ray energy (<10 MV).7–11 A Monte Carlo (MC) study
conducted by Kry et al.,7 showed a similar photon out‐of‐ﬁeld dose
for 6 MV compared to 18 MV intensity‐modulated radiation therapy
(IMRT) treatments. For the nine organ locations investigated, the
simulated neutron doses were typically much lower than the corre-
sponding photon dose. Nevertheless, they warranted an improved
neutron dosimetry in order to achieve superior estimates. Ruben et
al. 8 measured the components of the out‐of‐ﬁeld photon dose for 6
and 18 MV treatments. The neutron dose contribution was obtained
from published data. They reported that X‐ray energy does not
affect the total photon scatter for the same treatment technique.
However, the additional neutron dose for 18 MV may have
increased total body cancer risk compared to 6 MV IMRT treat-
ments. However, they were not able to draw a ﬁrm conclusion. Hälg
et al.12 used track etch detectors to measure neutron dose equiva-
lent in an anthropomorphic phantom for various treatment modali-
ties. For 15 MV external photon beam treatments, the neutron dose
was by factors lower compared to other literature.
With increasing number of treatments using volumetric‐modu-
lated arc therapy (VMAT) and similar dose distributions of VMAT
compared to IMRT treatments, the question arises about the dif-
ference in the out‐of‐ﬁeld dose between the two techniques. To
our knowledge, there is no study published comparing the periph-
eral dose (including neutrons) of high‐energy VMAT treatments
with IMRT treatments. In the current study, the difference
between the dose equivalent of 6 and 15 MV treatments was
examined. It is per se not clear that for 15 MV X‐ray nominal
beam energy the out‐of‐ﬁeld dose will be smaller in comparison
to 18 MV because of the reduced photoneutron production. Com-
pared to photons, neutrons are a minor part of the total out‐of‐
ﬁeld dose equivalent.1 Howell et al. 9 reported a higher effective
dose for 15 MV compared to 18 MV 3D‐conformal radiation ther-
apy (3DCRT) treatments.
Also the use of X‐ray imaging modalities can give a substantial
dose to the patient.13 The choice of treatment technique and indica-
tion determines the image modality and therefore, the additional
amount of dose to the patient. For patient positioning, the imaging
dose is justiﬁed by the reduction of the margins around the target. A
smaller planning target volume will lead to a sparing of the organs at
risk during irradiation. If image‐guided radiotherapy (IGRT) is used,
the patient receives an additional dose from X‐ray imaging. By
including all contributions of the whole‐body dose for an IGRT treat-
ment, a better understanding in radiation protection of the patient
can be achieved.
In the current study, we investigated the whole‐body dose equiv-
alent for 6 and 15 MV IGRT treatments of a rhabdomyosarcoma in
the prostate applied with three different techniques (3DCRT, IMRT,
and VMAT). The analytically calculated dose distributions were veri-
ﬁed with whole‐body dose measurements. The results from the cal-
culation were used to identify differences in the whole‐body dose
between the investigated treatments.
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2 | METHODS AND MATERIALS
In this manuscript, the indexes m, c, and s describe quantities which
were derived either from measurements, calculations, or MC simula-
tions, respectively. The abbreviation n stands for neutrons and γ for
photons.
2.A | Whole‐body photon and neutron dose
calculation
Dose calculations were performed for an anthropomorphic phantom
(Alderson‐Rando, RSD Radiology Support Devices, Long Beach, CA,
USA) using a whole‐body grid with a voxel dimension of
0.2 × 0.2 × 0.5 cm3 (see Fig. 1). However, the radiotherapy photon
and neutron dose models used in this work are generally applicable
to any 3D‐patient data set.
2.A.1 | Photon imaging dose
For each treatment fraction, the patient was assumed to be posi-
tioned with a full trajectory kV cone beam CT (CBCT) of the pelvis.
Hence, we assigned a relatively high imaging dose for the IGRT
treatments. The mean absorbed CT dose per Alderson slice was cal-
culated using the average of the thermoluminescence detector (TLD)
dose measurements in the corresponding slice. The TLD measure-
ments of the full trajectory pelvis CBCT are reported in Hauri et al.14
The absorbed dose per voxel of a CBCT scan was calculated by
interpolating the average CBCT dose per Alderson slab along the
medial patient axis (MPAX). Hence, the dose was the same for all
voxels in a transversal dose‐grid slice [see Fig. 1(a)]. According to
Schneider et al.,15 the dose of a full rotation CBCT is in a ﬁrst
approximation homogeneous in a transversal slice.
2.A.2 | Therapy dose photons and neutrons
A previously developed photon stray dose model for static and
intensity‐modulated 6 MV treatments 16 was improved and adapted
for 15 MV (see Appendix 1). The algorithm calculated the whole‐
body out‐of‐ﬁeld dose of the coplanar treatments starting 4 cm
longitudinal from the treatment volume (∼3 cm from the ﬁeld edge).
According to Kry et al.,1 the differences between treatment planning
system (TPS) and measurements exceed 30% of the local dose as
close as 3 cm from the ﬁeld edge, and differences increase by orders
of magnitude at greater distances. At 4 cm longitudinal from the
treatment volume, the dose of the TPS (Varian Eclipse, AAA‐algo-
rithm version 13.6.23) was fused with the model‐calculated 3D out‐
of‐ﬁeld dose resulting in a whole‐body photon dose [see Fig. 1(b)].
The peripheral neutron dose was calculated using an analytical
model from the literature.17 This model was commissioned for True-
Beam linear accelerators (linacs) (Varian Medical Systems, Palo Alto,
CA, USA), operated at 15 MV [see Fig. 1(c)]. The model assumed a
point source of neutrons in the X‐ray producing target to predict the
neutron ﬂuence in the Alderson phantom. The ﬂuence was con-
verted to a neutron dose equivalent according to Sibert and Schu-
macher.18 Only the peripheral neutron dose was calculated since
inside the primary X‐ray beam, the dose from neutrons can be
neglected when compared to the photon dose.12,19
2.A.3 | Whole‐body dose
To obtain a typical IGRT treatment dose, a daily CBCT 3D dose was
added to the 3D photon dose per session. For the 15 MV treat-
ments, the neutron dose equivalent per session was added. The
voxel‐speciﬁc dose equivalents per session were multiplied with the
number of sessions (see Table 1), resulting in the 3D dose equivalent
per treatment [see Fig. 1(d)].
2.B | Whole‐body TLD measurements
The whole‐body photon and peripheral neutron dose measurements
served as veriﬁcation of the photon stray dose and neutron dose
calculation.
LiF TLD‐chips (4.5 mm diameter, 0.6 mm thickness, Harshaw,
Thermo Fisher Scientiﬁc, Waltham, MA, USA) were used to measure
the in‐ and out‐of‐ﬁeld dose of external therapy. For TLD100 (LiF:
Mg,Ti) and TLD100H (LiF:Mg,Cu,P), the same thermal treatment, cal-
ibration procedure, and readout were used as described by Hauri
and Schneider.21 The thermal treatment, calibration procedure, and
F I G . 1 . The whole‐body dose equivalent
for the 15 MV IMRT treatment with a
daily CBCT. The dose equivalent is shown
for (a) 23 times a CBCT, (b) photon scatter
radiation fused with the treatment
planning system calculation, (c) neutrons
and (d) the summation of (a)–(c). The
Fractionation scheme is presented in
Table 1. Furthermore, the outline of the
rhabdomyosarcoma in the prostate can be
seen.
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readout for TLD600/700 (LiF:Mg,Ti) and TLD700H (LiF:Mg,Cu,P)
were the same as applied to TLD100 and TLD100H, respectively.
TLD100 contains the natural abundance of 6Li and 7Li, while
TLD600 contains primarily 6Li. According to Schwahofer et al.,22
TLD600 and TLD100 show the same response to photon radiation
since the number of neutrons in Li does not affect the energy bands
of the TLD crystal. For the same reason, it was assumed in this
manuscript that there is no difference in the response with photon
radiation energy of TLD100H and TLD700H.
For each TLD, an individual photon dose‐to‐water calibration fac-
tor (in mGy/count) was determined using 6 MV nominal X‐ray
energy applied with a TrueBeam linac. All absolute photon dose
measurements were correlated to a Farmer Chamber 30013 (PTW,
Freiburg, Germany). The irradiations and detector readouts were per-
formed according to a strict protocol21 to ensure consistency of the
measurements.
2.B.1 | Treatment intention, planning, and
irradiation
The target volume of this study was a rhabdomyosarcoma in the
prostate of an adolescent patient. The planning CT of the anthropo-
morphic Alderson phantom as well as the contouring of the target
volume and organs were performed at one hospital.
The treatment planning of the 6 and 15 MV 3DCRT (four ﬁeld
box), IMRT (ﬁve ﬁelds with dynamic multileaf collimator (MLC)), and
VMAT (one arc) treatments was done using the Eclipse TPS. All
treatments were planned by an experienced worker. The 3DCRT
treatments included a sequential boost and the intensity‐modulated
treatments an integrated boost. The motivation regarding the treat-
ment intention and the fractionation scheme, and a detailed descrip-
tion of the treatments and the strict planning guidelines can be
found in Hälg et al.20
The diameter of the pelvis CBCT was 46.5 cm in a transversal
slice and a ﬁeld‐of‐view of ±8.75 cm from the isocenter in the longi-
tudinal direction. The CBCT protocol (version 2.5.28.0, half‐fan type,
full trajectory, 125 kVp, 1080 mAs) was given by the vendor.
Using a conventional linac equipped with an on‐board imaging
system (TrueBeam), the six treatments and the CBCT were irradiated
onto the Alderson phantom, each time loaded with new TLDs. The
phantom was positioned head ﬁrst supine. For the 6 MV treatments
and the CBCT scan, each measurement location in and on the phan-
tom was equipped with a TLD100H stacked on top of a TLD100.
For the 15 MV treatments, each measurement location was loaded
with a TLD700H stacked on top of a TLD600. Confetti (made out of
normal paper) were placed between all (TLD600, TLD700H)‐pairs to
avoid an α‐particle contribution to the TLD700H signal originating
from the 6Li(n, α) capture. The measurement locations were dis-
tributed in the Alderson phantom according to Hälg et al.20 Addi-
tionally, for the 15 MV treatments, the out‐of‐ﬁeld photon dose of
the skin was measured along a line from the pelvis to the nose of
the phantom in steps of 10 cm. For this, the TLD700H were loaded
in empty pill casings made of PMMA simulating the thickness of the
skin. All absolute photon dose measurements were correlated to a
Farmer Chamber 30013 since the chamber was used to determine
the in‐ﬁeld TLD‐calibration dose.
2.B.2 | Photon dose and mean photon energy of
the CBCT and 6 MV treatments
The in‐ and out‐of‐ﬁeld photon dose of the 6 MV treatments and
the CBCT were measured separately using a combination of TLD100
and TLD100H chips. The two TLD types show a difference in
response with photon radiation energy.22,23 If calibrated with 6 MV
nominal beam energy, TLD100 show an over‐ and TLD100H an
under‐response toward lower energy (down to 0.1 MeV).21 By build-
ing the ratio of the TLD100 and the TLD100H measured doses, the
mean photon energy can be determined. Using the photon energy at
a speciﬁc measurement location, the TLD correction factors for the
response with radiation energy can be determined. A comprehensive
description of photon dose and the mean energy measurements for
the CBCT and the 6 MV treatments is given in Hauri and Schnei-
der.21 Furthermore, a detailed description of the uncertainties in
photon dose and mean photon energy is presented.
2.B.3 | Photon dose of the 15 MV treatments
The whole‐body photon dose of the 15 MV treatments was deter-
mined for 189 locations in the Alderson phantom. The detected out‐
of‐ﬁeld photon dose by each TLD700H was corrected for the
response with photon radiation energy. The individual correction fac-
tors were estimated by using the photon scatter contribution at each
measurement location in the phantom.
The total out‐of‐ﬁeld photon dose consists mainly of three contri-
butions: patient scatter, collimator scatter, and head leakage.8,16,24 In
the middle of a 30 × 30 × 30 cm3 water‐slab phantom (source sur-
face distance = 85 cm), the mean energy of the three scatter contri-
butions was measured using a combination of TLD700 and
TLD700H.21 For a 10 × 10 cm2 ﬁeld (deﬁned by the MLC), the mean
energy of patient scatter was measured at 15 cm distance to the ﬁeld
edge. For the same ﬁeld size, the mean energy of collimator scatter
was determined at 15 and 35 cm distance from the ﬁeld edge. At the
TAB L E 1 The total treatment dose, total MUs, and MUs per
treatment Gy. The treatments were planned by an experienced
worker according to a strict protocol.20
Plan
Treatment
dose
×fractions Beam Total MUs
MUs per
treatment
Gy
3DCRT 2.0 Gy × 26 = 52.0 Gy 6 MV 7326 MUs 141 MUs/Gy
15 MV 5846 MUs 112 MUs/Gy
IMRT 2.2 Gy × 23 = 50.6 Gy 6 MV 22989 MUs 454 MUs/Gy
15 MV 21661 MUs 428 MUs/Gy
VMAT 2.2 Gy × 23 = 50.6 Gy 6 MV 13409 MUs 265 MUs/Gy
15 MV 11847 MUs 234 MUs/Gy
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same locations, the mean energy of head leakage was measured for
closed jaws and MLC. The separation of a ﬁeld measurement into the
three scatter contributions is described by Hauri et al.16
A previously developed 6 MV out‐of‐ﬁeld dose model16 was
improved and adapted for 15 MV (see Appendix 1). Using the
adapted model, the doses of patient scatter, collimator scatter, and
head leakage were calculated for each measurement location l in the
phantom. The ﬁnal out‐of‐ﬁeld mean energy Eγl;c was determined by,
E
γ
l;c ¼
1
∑iD
γ
i;l;c
∑iD
γ
i;l;c  E
γ
i;m; (1)
with i = {patient scatter, collimator scatter, head leakage}. Dγi;l;c is the
calculated dose at the measurement location l and Eγ
i;m
; is the mean
energy of the scatter contribution i.
The calculated out‐of‐ﬁeld mean energies were used to deter-
mine the individual correction factors for the response with photon
radiation energy of the TLDs. The multiplication of individual correc-
tion factors with the TLD700H‐detected dose resulted in the ﬁnal
photon dose.
As a consistency check, the TLD correction factors for the
response with photon radiation energy were calculated for the 6 MV
treatments (3DCRT, IMRT, and VMAT). In distinction to the 15 MV
measurements, the photon energies for the 6 MV treatments were
explicitly measured.21 Using Eq. 1, the mean photon energy was cal-
culated for each measurement location of the 6 MV treatments. The
calculated and measured mean energies were converted to correc-
tion factors for the TLD100H response with photon radiation
energy. The calculated and measured correction factors for the
6 MV treatments were compared to estimate the uncertainty of the
TLD700H photon dose measurement.
2.B.4 | Neutron dose equivalent of the 15 MV
treatments
With a combination of TLD600 and TLD700H, the whole‐body neu-
tron dose equivalent of the 15 MV treatments was determined.
TLD700H is not affected by neutrons in the energy range of inter-
est.25 TLD600 register photons and neutrons. Using the mean photon
energy (Eq. 1), the neutron signal detected by TLD600 in the phan-
tom was corrected for the photon contamination measured by
TLD700H. The measured neutron signal of a TLD600 was trans-
formed to neutron dose equivalent (including fast neutrons) with a
depth dependent conversion factor.17 Each TLD600‐speciﬁc depth in
the phantom was calculated by using a straight line connecting the
X‐ray producing target and the measurement location. The Alderson
phantom was assumed to be a soft tissue‐equivalent (ICRU), with the
exception of the lungs. For the lungs, a mass density of 0.25 × ρ soft
tissue was assumed (relative hydrogen content in lungs compared to
soft tissue = 25% 26). For the 3DCRT and the IMRT treatments, the
calculation of the depth in the phantom was straight‐forward since
there was no gantry rotation during the beam‐on time. For the VMAT
treatment, the control points of the one arc were grouped to six ﬁelds
with different gantry angles and corresponding MUs per ﬁeld. A more
detailed description of the approximation of the VMAT plan by dis-
crete ﬁelds can be found in Hauri et al.16
Compared to the TLD600‐registered signal from neutrons, the
signal from photons is orders of magnitude higher in the target vol-
ume.27 Therefore, the measurement of neutron dose equivalents
was only possible outside the treatment volume.
3 | RESULTS
Unless otherwise stated, the mean and one standard deviation (σ)
are presented. Consistent with the IAEA report,28 type A stands for
the measured σ and the type B for the estimated σ.
3.A | Whole‐body dose equivalent
3.A.1 | Photons
The deviation between the calculated whole‐body dose and the 183
point‐dose measurements of the CBCT scan was 0% ± 14% (type A).
The measured mean photon energies of the three stray dose
contributions can be seen in Table 2. Within the measurement
uncertainties, there was no difference in the mean energies of the
scatter contributions between the 15 and 6 MV ﬁeld measurements.
The measured mean energy of head leakage was the same at 15 and
35 cm distance from the ﬁeld edge. For a nominal X‐ray energy of
15 MV, the mean energy of collimator scatter changes from
>1.1 MeV at 15 cm to 0.5 MeV at 35 cm distance from the ﬁeld
edge. A similar change in the mean energy of collimator scatter was
noticed for the 6 MV nominal X‐ray energy. However, close to the
ﬁeld edge, patient scatter is the dominating scatter contribution,16,24
whereas the biggest contribution of collimator scatter relative to the
other contributions is at around 35 cm distance from the ﬁeld edge
[see Figs. 2(b)–2(d)]. Hence, the mean energy of collimator scatter
determined at 35 cm was used to calculate the ﬁnal out‐of‐ﬁeld
mean energy for every measurement location [see Eq. (1)].
The average mean photon energy measured for all out‐of‐ﬁeld
TLD locations and the three 6 MV treatments was (0.40 ± 0.07) MeV
(type A). For the same locations and treatments, an average mean
photon energy of (0.40 ± 0.03) MeV (type A) was calculated. For the
15 MV treatments, an average mean photon energy of (0.47 ± 0.05)
MeV (type A) was calculated. Hence, the TLD measurements of the
TAB L E 2 The measured mean energies (Eγi;m) with the type B
uncertainty (σ=
ﬃﬃﬃ
n
p
with n as the number of measurements) for
i = patient scatter (ps), collimator scatter (cs), and head leakage (hl).
The uncertainties were calculated according to Hauri and
Schneider.21
Nominal X‐ray energy
Eγi;m [MeV]
ps cs hl
6 MV 0.28 ± 0.03 0.62 ± 0.07 0.35 ± 0.03
15 MV 0.29 ± 0.03 0.53 ± 0.04 0.45 ± 0.04
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15 MV treatments needed similar corrections for the response with
photon radiation energy as for the 6 MV treatments.21
For the 6 MV plans, the deviation between the calculated and
measured correction factors for the TLD100 response with photon
radiation energy was (0 ± 1) % (type A). For TLD100H, the deviation
between calculated and measured correction factors was (−1 ± 1) %
(type A). Using Gaussian error propagation, the uncertainty in the
TLD700H dose measurement was determined to ±2% (type B)
(σ = ±2% (type B) from the correction factor for the response with
photon radiation energy and σ = ±1% (type A) from the raw
TLD700H dose measurement 21).
In Fig. 3, the different out‐of‐ﬁeld dose contributions for a
VMAT treatment can be seen. For the 6 MV treatment, patient scat-
ter was the largest out‐of‐ﬁeld dose contribution. For 15 MV, colli-
mator scatter was larger compared to patient scatter. Furthermore,
the CBCT reached dose levels comparable to collimator scatter.
Averaged over all 15 MV treatments (3DCRT, IMRT, and VMAT),
the deviation between the calculated whole‐body out‐of‐ﬁeld photon
dose and the measurement was (8 ± 10) % (type A) [Fig 2 (a)]. For
the 6 MV treatments, the deviation between calculated and mea-
sured out‐of‐ﬁeld photon dose was (10 ± 10) % (type A).
The photon dose calculated by the TPS was compared to the
measurement in the transversal Alderson slices located 3 and 6 cm
from the treatment volume. In the out‐of‐ﬁeld region, the deviation
between the TPS‐calculated and measured photon dose for the
three 15 MV and three 6 MV treatments was (−5 ± 21) % and
(8 ± 11) % (type A), respectively. For the same measurement loca-
tions, the deviation between the algorithm‐calculated and the mea-
sured photon dose was (−10 ± 13) % and (−1 ± 15) % (type A) for
the 15 and 6 MV treatments, respectively. The agreement of the
algorithm‐/TPS‐calculated dose and the TLD‐measured photon dose
in the overlap region, justiﬁed the fusion of TPS and algorithm dose
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F I G . 2 . (a) The 438 out‐of‐ﬁeld TLD700H photon dose point measurements in the Alderson phantom (head ﬁrst supine) compared to the
algorithm‐predicted doses for the three 15 MV treatments. Furthermore, the TPS‐calculated dose, the stray dose contributions, the total
predicted doses fused with the TPS dose, and the measured doses along the MPAX for (b) the 3DCRT, (c) the IMRT, and (d) the VMAT
treatment applied with a TrueBeam are shown. The vertical dashed lines in (b)–(d) represent the ﬁeld edge calculated by the out‐of‐ﬁeld dose
algorithm. Additionally, the measured skin dose along a line from the pelvis to the nose of the Alderson phantom is plotted.
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at 4 cm from the target volume. The fused photon dose compared
to the measurement along the MPAX can be seen in Figs. 2(b)‐(d). In
the same ﬁgures, the measured photon skin dose for the 15 MV
treatments along a line from the pelvis to the nose of the phantom
is plotted. For all treatments, the VMAT showed the largest and the
IMRT the lowest skin dose relative to the measured dose along the
MPAX. The improved stray dose algorithm underestimated the skin
dose up to a factor of two.
3.A.2 | Neutrons
In Fig. 4, the measured and calculated neutron dose equivalent along
the MPAX can be seen. The calculation and measurements were in
good agreement. The large photon signal relative to the neutron sig-
nal close to the target volume resulted in a large uncertainty in the
neutron dose equivalent. However, the uncertainty resulting from
the photon contamination was below ±10% (type B) at locations
≥3 cm from the target volume. The overall uncertainty in the mea-
sured neutron dose equivalent was below ±30% (type B) at locations
≥3 cm from the target volume. The difference between the calculated
and measured neutron dose equivalent was 18 ± 27% (type A) for
the three 15 MV treatments. Hence, the calculation and the mea-
surement were in agreement within the measurement uncertainties.
The calculated and measured neutron dose equivalent showed a
strong dependence with depth. There was no signiﬁcant difference
(α < 0.05) in the measured neutron dose equivalent per MU along
the MPAX between the 3DCRT, IMRT, and VMAT treatment. How-
ever, for measurement points close to the surface, the treatments
showed signiﬁcant differences in neutron dose equivalent. The neu-
tron dose close to the surface was dependent on the gantry angles
of the treatment ﬁelds. The neutron model overestimated the dose
equivalent in the lungs.
3.A.3 | Total dose equivalent
In Figs. 5(a) and 5(b), the out‐of‐ﬁeld contributions to the total dose
equivalent volume histograms (DEVHs) of the IMRT and the 3DCRT
15 MV treatments are plotted (on a logarithmic scale). There was
good agreement between the photon DEVH determined by the 151
out‐of‐ﬁeld measurement points and DEVH determined by the calcu-
lated photon dose. The DEVHs of the VMAT treatments (not plot-
ted) were between the DEVHs of the 3DCRT and the IMRT
treatments. For all energies and treatment techniques, the photon
stray dose caused by the primary beam was the biggest contribution
to the total out‐of‐ﬁeld dose. At the edge of the CBCT ﬁeld‐of‐view,
the daily CBCT dose reached levels comparable to the 3DCRT out‐
of‐ﬁeld dose [Fig. 5(b)]. In Figs. 5(c) and 5(d), the whole‐body DEVH
of the 6 and 15 MV treatments can be seen. For the same treatment
technique, the DEVHs showed only small differences between the
two beam energies.
Outside the target volume, the deviation between the calculated
and measured ﬁnal dose equivalent was (10 ± 11) % and (8 ± 8) %
(type A) for the 15 MV and the 6 MV treatments, respectively. The
measured uncertainty in the ﬁnal dose equivalent was similar to
the uncertainty in the photon scatter dose since the stray dose was
the biggest contribution of the total dose equivalent.
In Fig. 6, the whole‐body DEVHs of the different treatment
techniques are shown. In the high and intermediate dose region
(>3 Sv or 5% of the prescribed dose), the DEVHs for the inten-
sity‐modulated treatments were similar. In the same dose region,
the DEVHs of the 3DCRT treatments were different from the
intensity‐modulated treatments. For the same beam energy, the
minimum dose of the 3DCRT treatment was two times lower than
for the VMAT treatment and four times lower than for the IMRT
treatment.
6 MV VMAT Outside the Treatment Region
0 100 1000
Dose [mSv/whole treatment]
0
20
40
60
80
100
Vo
lu
m
e 
(%
)
CBCT
ps
cs
hl
total
15 MV VMAT Outside the Treatment Region
1 1 1 10 100 1000
Dose [mSv/whole treatment]
0
20
40
60
80
100
Vo
lu
m
e 
(%
)
CBCT
ps
cs
hl
n
total
(a) (b)
F I G . 3 . The out‐of‐ﬁeld contributions (CBCT: 23 times a daily CBCT dose, ps: patient scatter, cs: collimator scatter, hl: head leakage, n:
neurons dose equivalent) to the total DEVHs for the VMAT treatments applied with (a) 6 MV and (b) 15 MV nominal X‐ray energy.
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4 | DISCUSSION
Averaged over all treatment techniques and nominal X‐ray energies,
the calculated whole‐body dose equivalent agreed within (9 ± 10) %
(type A) compared to the measured dose equivalent. This agreement
was sufﬁcient to determine differences in the whole‐body dose
between the investigated treatments.
4.A | Photon dose
The small deviation between the predicted and measured CBCT
dose justiﬁed the presented method to calculate the whole‐body
imaging dose.
Close to the target volume, the CBCT dose was a substantial
contribution to the out‐of‐ﬁeld dose resulting from a treatment
(Fig. 5). In the ﬁeld‐of‐view of the CBCT, the dose was almost con-
stant.29 Furthermore, the ﬁeld‐of‐view extended around 4 cm over
the border of the target volume. In this area, the dose caused by
scatter radiation of the primary beam dropped rapidly with increas-
ing distance to the target volume. The CBCT dose decreased expo-
nentially with increasing distance to the ﬁeld‐of‐view. Hence, a
smaller ﬁeld‐of‐view is beneﬁcial regarding radiation protection of
the patient. The contribution of imaging to the total dose equivalent
was similar for all investigated treatments since the number of ses-
sions and the fraction doses were comparable for all treatments (see
Table 1). It follows that the results obtained in this work are valid
even if the imaging dose is excluded from the comparisons. A
detailed discussion of the CBCT dose in context of the treatment
dose can be found in the literature.14
The mean photon energies calculated/measured outside the
treatment volume were in agreement with reported out‐of‐ﬁeld
mean energies for 6 and 15 MV (static ﬁelds deﬁned by the MLC or
IMRT ﬁelds).30–32 Kry et al.30 simulated the same average photon
energy (0.4 MeV) for a 6 MV ﬁeld (deﬁned by the MLC) as we calcu-
lated/measured in the current work. Using the simulated average
mean energy, they applied an overall correction factor for TLD100
to correct the out‐of‐ﬁeld dose measurements. However, a general
correction factor leads to a systematic error in dose.21,31 Using the
presented method to calculate the mean photon energy, this system-
atic error in the dose correction can be avoided.
The spectrum of patient scatter for a Simens Primus 6/15 linac
was MC simulated by Chofor et al.33 A similar photon energy of
patient scatter for 6 and 15 MV beams was reported. This is in
agreement with our work. Photons of lower energies have an
increased probability of large Compton scatter angles compared to
high‐energy photons. Hence, particularly photons of lower energies
from the primary X‐ray spectrum cause patient scatter. The ﬂuence
ratio of low‐energy photons to high‐energy photons is larger for
6 MV than for 15 MV beams. This could be one of the reasons
why patient scatter dose was higher for 6 MV than for 15 MV
treatments.
Compared to the primary beam, the X‐ray spectrum in the
peripheral region is softer such that an increase in organ‐speciﬁc rel-
ative biological effectiveness (RBE) for carcinogenesis is expected.34
With the presented method, the dose and corresponding mean pho-
ton energy can be calculated separately for patient scatter, collima-
tor scatter, and head leakage. Hence, for every scatter contribution,
a separate RBE for cancer induction can be determined.
Close to the ﬁeld edge, where patient scatter and collimator
scatter dominated (see Fig. 2), the 6 MV treatments showed a higher
dose than the 15 MV counterparts. This is in agreement with a MC
study from the literature.35 For a standard ﬁeld, patient scatter was
increased by a factor of two for 6 MV compared to 15 MV (Fig. 8),
whereas collimator scatter was reduced just by a factor of 1.5 for
6 MV compared to 15 MV (Fig. 9). This factor was reduced further
because collimator scatter scales with the applied MUs16 and the
6 MV treatments needed more MUs compared to the 15 MV treat-
ments (Table 1).
Ruben et al.8,24 measured the components of the out‐of‐ﬁeld
dose for IMRT and 3DCRT ﬁelds up to a distance 40 cm from the
F I G . 4 . The measured (points) and calculated (solid lines) neutron
dose equivalent for the 3DCRT, IMRT, and VMAT treatments along
the MPAX. For the measurements, a TrueBeam linac operated at
15 MV nominal X‐ray energy was used. The 95% conﬁdence interval
for the measured neutron dose equivalent (indicated by the error
bars) decreased rapidly from ±100% to ±40% (type B) with
increasing distance to the central ﬁeld axis. The dashed line indicates
the edge of the target volume. Furthermore, the Alderson phantom
with the outline of the target volume (rhabdomyosarcoma) in the hip
region can be seen. The arrow represents the MPAX and is scaled to
the upper ﬁgure.
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isocenter. In agreement with our work, they reported a decreasing
patient scatter dose for increasing nominal X‐ray energy. Further-
more, they measured nearly the same 3DCRT out‐of‐ﬁeld dose for 6
and 15 MV treatments. In their study, both 3DCRT treatments uti-
lized the same MUs. We noticed an overall lower photon dose with
the 15 MV than with the 6 MV 3DCRT treatment. In our study, lesser
MUs were needed to apply the 15 MV than the 6 MV treatments.
The improved general model for stray dose calculation16 pre-
dicted the measured off‐axis photon dose contribution in the anthro-
pomorphic phantom well. To our knowledge, this is the only
analytical model for whole‐body photon dose prediction for static
and intensity‐modulated treatments. An analytical model to calculate
the out‐of‐ﬁeld dose for intensity‐modulated treatments was intro-
duced by Sanchez et al.32 Their model is only applicable for dis-
tances ≥10 cm from the ﬁeld edge because they neglected the
patient scatter contribution. However, close to the ﬁeld edge, the
largest out‐of‐ﬁeld dose gradients are present. Furthermore, the TPS
cannot be used to calculate the out‐of‐ﬁeld dose up to 10 cm from
the ﬁeld edge since differences between TPS and measurements
exceed 30% of the local dose as close as 3 cm from the ﬁeld edge,1
and differences increase by orders of magnitude at greater distances.
An aspect of neutron interaction in the phantom is the produc-
tion of capture gamma‐ray emission. The dose contribution from this
emission can be neglected for photon radiotherapy since it is small
compared to the scatter photon dose of the primary beam.19 How-
ever, using TLD700H the capture gamma rays were measured
together with the scatter photon dose. Furthermore, the capture
gamma‐ray contribution was included in the predicted head leakage
dose since the scatter dose model was adjusted using ionization
chamber measurements (see Appendix 1). The TLD700H measure-
ments agreed well with the calculated stray dose in the off‐axis
region, where head leakage was dominating [see Figs. 2(b)–2(d)].
(a) (b)
(c) (d)
F I G . 5 . Out‐of‐ﬁeld DEVHs of the various contributions (CBCT: daily CBCT dose × number of treatment sessions, n: neutron dose
equivalent, γ: photon dose) and the total dose for the 15 MV (a) IMRT and (b) 3DCRT plan per whole treatment. “γ 15 MV” indicates the
calculated whole‐body photon dose. “γ 15 MV measured” was determined from the 151 out‐of‐ﬁeld measurement locations distributed in the
Alderson phantom. In (c) for IMRT and (d) for 3DCRT, the in‐ and out‐of‐ﬁeld whole‐body DEVHs for the 6 MV and the 15 MV treatments are
plotted.
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4.B | Neutron dose equivalent
Compared to the measurements, the model overestimated the neu-
tron dose in the phantom in average by 18%. The overestimation
was larger for the 3DCRT compared to the IMRT treatment. The
3DCRT treatments showed an average ﬁeld opening of around
9 × 10 cm2 compared to an opening of 3 × 10 cm2 for the IMRT
treatments. Howell et al.36 measured less neutron ﬂuence per MU
for a 3DCRT than for an IMRT treatment. The MLC are an additional
source of photoneutron production.1 The model was commissioned
for closed jaws and MLC and therefore, it predicts a conservative
estimate of the neutron dose equivalent for a patient treatment.
Within the uncertainties, the prediction by the neutron dose
model was in agreement with the measurements. Along the MPAX,
the neutron dose peaked in the neck of the Alderson phantom for
the calculation as well for the measurement (Fig. 4). The reason for
this is that in the neck region, the neutrons penetrated the smallest
amount of tissue to reach the MPAX compared to other parts of the
phantom. The largest overestimation in neutron dose by the model
compared to the measurements was seen in the lungs. A simple scal-
ing with the density of the lungs was used to calculate the depth in
the anthropomorphic phantom. A wrongly assumed density for lung
tissue can explain the overestimation in neutron dose.
H¨alg et al.12 measured the neutron dose equivalent using track
etch detectors for the same treatment intention and techniques as
presented in the current work. For all treatments, the detectors
showed a systematic three times reduced neutron dose equivalent
per MU compared to the results presented here. Along the MPAX,
there was no signiﬁcant difference in the neutron dose equivalent
per MU between the three different techniques. Hence, the neutron
dose equivalent inside the phantom scaled with the applied MUs
independently of the treatment technique. This was not true for the
neutron dose per MU closer to the phantom surface. Close to the
surface, the neutron dose showed a signiﬁcant difference between
the three 15 MV treatment techniques (3DCRT, IMRT, VMAT). Neu-
tron dose close to the surface was strongly dependent on gantry
angle of the treatment ﬁelds.
4.C | Total dose equivalent
The DEVHs of the calculated photon stray dose were in good agree-
ment with the DEVHs of the measurement (Fig. 5). Hence, the mea-
surement locations represented a whole‐body photon dose well. In
comparison, DEVH of the calculated neutron dose equivalents
showed more dose per volume than the DEVHs from the measure-
ments. This can be explained by the fact that most of the TLD mea-
surement locations were deeper than 1 cm in the phantom.20 The
locations were chosen such that they cover all ICRP‐recommended
organs.37 The neutron dose decreases rapidly with increasing depth
in the phantom [Fig. 1(a)]. In terms of radiation protection, the high
neutron dose contribution down to 1 cm in the patient is of less
importance since most ICRP organs are located deeper in the body.
For high and intermediate doses (>3 Gy or 5% of the prescribed
dose), the DEVHs for the same technique were similar for the two
nominal X‐ray energies [Figs. 5(a) and 5(b)].
The out‐of‐ﬁeld dose close to the target volume was higher for
6 MV than for 15 MV. Patient scatter and to a lesser extend collima-
tor scatter are the dominating out‐of‐ﬁeld dose contributions close
to the target volume. 6 MV nominal X‐ray energy showed a two
times increased patient scatter and a similar collimator scatter contri-
bution compared to 15 MV (see Appendix 1). This explained the lar-
ger body volume receiving doses of 0.2–3 Sv for 6 MV compared to
15 MV [Figs. 5(c) and 5(d)]. At around 50 cm from the isocenter,
head leakage and neutrons were the dominating out‐of‐ﬁeld dose
contributions [Figs. 2(b)–2(d)]. Hence, for doses <0.2 Sv, the differ-
ences in the DEVHs were dependent on the difference between
head leakage of 6 MV compared to head leakage and neutron dose
of 15 MV. Head leakage and neutron dose scale linearly with MU
Whole−Body Dose Equivalent
10 100 1000 10000
Dose Equivalent [mSv/whole treatment]
0
20
40
60
80
100
Vo
lu
m
e 
(%
)
6 MV 3DCRT
6 MV IMRT
6 MV VMAT
Whole−Body Dose Equivalent
10 100 1000 10000
Dose Equivalent [mSv/whole treatment]
0
20
40
60
80
100
Vo
lu
m
e 
(%
)
15 MV 3DCRT
15 MV IMRT
15 MV VMAT
(a) (b)
F I G . 6 . The whole‐body DEVHs for (a) the 6 MV (b) the 15 MV treatments.
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and are in a ﬁrst approximation independent of the ﬁeld shape.1 The
relative difference in MUs for the 6 MV compared to the 15 MV
treatment was smaller for the intensity‐modulated treatments when
compared to the 3DCRT treatments (see Table 1). This explained the
crossing of the 6 and 15 MV DEVHs for the intensity‐modulated
treatments at 0.2 Sv (see Fig. 5c). For the 3DCRT treatments, the
DEVH of the 15 MV plan was equal or below the 6 MV DEVH.
Hence, regarding radiation protection of the patient, the 3DCRT
15 MV treatment was superior compared to the 6 MV treatment.
Head leakage and neutron DEVHs can be seen in Fig. 7.
Head leakage was almost constant in the phantom, whereas neu-
tron dose was inhomogeneous. For all techniques, the minimum
dose was higher for 6 MV than for 15 MV. This was caused by a
smaller leakage dose for 15 MV than for 6 MV (Fig. 9) and the low
neutron dose in the center of the body [Fig. 1 (c)]. Head leakage is
assumed to be reduced because of more forward‐directed photons
in the X‐ray producing target for 15 MV than for 6 MV.
Between 15 and 6 MV, the dose equivalent was similar for the
same treatment technique such that the resulting cancer risk might
not be clinically observable. Independent of the nominal X‐ray
energy, the dose equivalent in the low and intermediate dose
region was increased by a factor of two for the VMAT compared
to the 3DCRT treatment and by a factor of four for the IMRT com-
pared to the 3DCRT treatments. Using VMAT, similar dose distribu-
tions in the target volume can be achieved as for IMRT.38
However, the out‐of‐ﬁeld dose is different between the two tech-
niques, favoring VMAT for radiation protection of the patient. This
is because usually a shorter beam‐on time is needed for VMAT
compared to IMRT and collimator scatter, head leakage, and neu-
tron dose are linearly scaling with the applied MUs. Varian linacs
have been shown to produce the most photoneutrons compared to
other vendors.1 This has raised concerns about radiation protection
of the patient when treating with Varian linacs operated at nominal
X‐ray energies higher than 10 MV.7,39 Far from the treatment
region (>50 cm), the photoneutron dose equivalent was similar to
head leakage. Neutron dose and head leakage scaled with the
applied MUs. Varian accelerators (600C, 21‐iX) show a reduced
leakage dose compared to other vendors (Elekta Synergy‐II, Siemens
Primus).40 Hence, regarding radiation protection of the patient for
high‐energy treatments, the choice of treatment machine should
not only be based on neutron production but rather on the total
dose equivalent including photon scatter.
Multiple studies reported an increased cancer risk based on an
increased dose equivalent for high energy compared to low‐energy
radiotherapy.35,39 The increased dose equivalent for high compared
to low‐energy X‐ray therapy was reported to be caused by the
additional neutron dose. However, the neutron energies in these
publications were overestimated resulting in an overestimation of
neutron dose. An extensive discussion of the overestimation in
neutron dose reported by the literature can be found in Kry et al.7
For the same treatment technique, we did not notice an increase
in the whole‐body dose equivalent for increasing nominal X‐ray
energy (up to 15 MV). For IMRT treatments, the ﬁndings are in
agreement with an MC study made by Kry et al.7 They found that,
the calculated 6 and 18 MV out‐of‐ﬁeld doses were similar for
IMRT.
A shortcoming of this study is that the investigation was focused
only to one treatment location (rhabdomyosarcoma in the prostate).
In addition, the whole‐body doses were calculated using an anthro-
pomorphic phantom and not a patient CT. This had the advantage
that the calculation could be directly compared to the measure-
ments. Nevertheless, the dose models used in this manuscript are
applicable to other treatment locations and patient geometries. The
photon dose calculated using the stray dose model16 was in good
agreement (absolute mean deviation of 22%) with whole‐body dose
measurements of 6 MV treatments for Hodgkin disease (involved
ﬁeld and involved node), and for treatments of an ependymoma in
the head (3DCRT, IMRT, and VMAT).41 Regarding out‐of‐ﬁeld dose,
F I G . 7 . Head leakage (hl) and neutron (n) DEVH for (a) the IMRT and (b) the 3DCRT treatments.
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further investigations are planned for different treatment indications.
These investigations are urgently needed.5
The calculated CBCT dose distribution was based on whole‐body
measurement. It is time consuming and not practical to measure the
dose of various CBCT protocols. Furthermore, the choice of the pro-
tocol inﬂuences the dose distribution in the ﬁeld‐of‐view region.29
Analytical models to calculate the CBCT dose are available but they
lack the ability to calculate the dose outside the ﬁeld‐of‐view.42
We did not include the out‐of‐ﬁeld dose caused by electron con-
tamination. Outside the primary beam, the dose close to the surface
can be increased by a factor of 4 compared to inside the body
(>2 cm).10 However, most critical organs are located in a patient
depth outside the reach of these electrons. Furthermore, usually
treatments are applied using multiple gantry angles, which reduces
the increased surface dose caused by electron contamination com-
pared to the dose in larger depths [see Figs. 2(b)–2(d)]. Nevertheless,
the skin dose was underestimated by the photon dose algorithm
used in this work.
For the calculation of the total whole‐body dose of a real patient,
the planning CT can be fused with a phantom containing the con-
tours of critical tissues.43 Such a feature is not yet clinically available.
Using the application programming interface of the Eclipse TPS, it is
planned to fuse the limited patient CT with a computational human
phantom from a library to generate a whole‐body representation of
the patient.
5 | CONCLUSION
The calculated whole‐body dose equivalent for IGRT treatments helped
to understand the importance of the scatter contributions in different
areas of the patient body. The calculations agreed well with measure-
ments and reported values from the literature. For intensity‐modulated
treatments, VMAT should be used instead of IMRT because of its
shorter beam‐on time, which reduces the out‐of‐ﬁeld dose.
One of the novelties in this paper was the analytically calculated
mean photon energy for every point in the patient outside the pri-
mary beam. The calculated energies agreed with measurements and
reported values from the literature. The mean photon energy can be
used to correct for a variation in response of a detector and to esti-
mate the RBE for the scatter contributions.
The neutron dose calculated by the model overestimated the
neutron dose equivalent by around 20% compared to the measure-
ments. The relatively small error in photon dose calculations com-
pared to the relative large error in neutron dose equivalent reduced
the overall error to around ±20% (type B) since the photon dose
was the main contributor to the out‐of‐ﬁeld dose.
Second cancer risk estimations are limited by the errors in the
risk model and the whole‐body dose calculation. In this work, the
accuracy and precision of the dose estimation were improved. Fur-
ther research should be carried out to improve cancer risk models
and whole‐body dose calculations to achieve better estimates in sec-
ond cancer induction.
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APPENDIX 1
6 MV AND 15 MV PHOTON SCATTER
MODELS
A general model for photon stray dose calculation developed for a
TrueBeam operated at nominal X‐ray energy of 6 MV16 was
improved and adjusted for 15 MV. The total absorbed dose outside
the treatment ﬁeld Dt can be described as the sum of three
contributions,
Dt ¼ Dps þ Dcs þ Dhl (2)
Patient scatter Dps is the dose mainly produced by Compton
scatter photons of the treatment ﬁeld penetrating the patient. Pho-
tons of the primary ﬁeld scattered at the jaws and MLC are
described by collimator scatter Dcs. Head leakage is the out‐of‐ﬁeld
dose contribution from photons which originate from the X‐ray pro-
ducing target and leaking through the gantry head shielding Dhl.
Patient scatter model
The four parameters of the mechanistic model of patient scatter
see [Eq. (8) from Hauri et al.16] were adapted for 15 MV nominal
X‐ray energy. The total absorbed dose was measured in simple
geometries using a Rigid Stem ionization chamber 30016 (PTW,
Freiburg, Germany). Patient scatter was extracted from the total
out‐of‐ﬁeld measurement and the four physically motivated ﬁt
parameters were determined. In Table 3, the evaluated parameters
for 15 MV nominal X‐ray energy can be seen. For comparison,
the parameters for 6 MV are shown, too. The ﬁeld width and
attenuation coefﬁcient [CW and μ
γ
ps)] showed almost no difference
between the two nominal X‐ray energies. However, the backscat-
ter contribution constant CB showed a clear decrease for 15 MV
compared to 6 MV. Furthermore, the normalization constant CN
describing the magnitude of patient scatter decreased by a factor
of 1.8 for 15 MV compared to 6 MV.
In Fig. 8, we see the comparison between patient scatter result-
ing from 15 to 6 MV nominal X‐ray energy. The normalized patient
scatter as a function of ﬁeld widths and lengths showed no differ-
ence between 15 and 6 MV [Fig. 8(a)]. The absolute patient scatter
dose 15 cm from the ﬁeld edge along a line parallel to the central
ﬁeld axis (R‐dependence 16) showed a higher dose for 6 MV than for
15 MV [Fig. 8(b)].
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For 6 MV, Chofor et al.33 simulated an almost twofold increase
in patient scatter compared to 15 MV. Ruben et al.8 measured a
1/3 higher patient scatter dose for 6 MV than for 18 MV. How-
ever, the difference in patient scatter between two nominal X‐ray
energies is dependent on the location in the patient, as can be
seen in Fig. 8(b). Patient scatter is independent from the beam
head design and is an unavoidable result of external radiother-
apy.33 Table III shows that primarily the normalization constant of
the patient scatter model has to be adjusted when using different
beam energies. The normalization constant can be determined by
one measurement set‐up. However, for ﬂattening ﬁlter free beams,
all model parameters could be different compared to ﬂattening ﬁl-
ter beams.
Collimator scatter and head leakage models
The empirical models of collimator scatter and head leakage16 were
improved. For 6 and 15 MV nominal X‐ray energy, collimator scatter
and head leakage were measured with a Rigid Stem ionization cham-
ber placed in a 30 × 30 × 30 cm3 RW3 phantom. For the measure-
ment, the phantom was moved along the MPAX. All measurements
of collimator scatter and head leakage are discussed for locations in
the direction “isocenter towards gun” and collimator rotation of 0◦.
For each energy, the measurements were made at different
depths in the RW3 phantom (7 cm, 15 cm, 23 cm) with and without
a lateral displacement of 8 cm from the MPAX. This resulted in nine
dose curves parallel to the MPAX, assuming lateral symmetry for col-
limator scatter and head leakage. Collimator scatter was measured
for different symmetric ﬁeld sizes deﬁned by the MLC. Head leakage
was measured by closing the jaws and MLC. The dose between the
TAB L E 3 The four measured parameters for the patient scatter model [Eq. (8) from Hauri et al.16] and the attenuation of the primary beam
(pb).
Beam CW CN CB μðEγpsÞ μðEγpb;1010cm2 Þ44
6 MV 0.845 0.724 mGy/Gy 0.203 0.007 22 mm−1 0.005 41 mm−1
15 MV 0.857 0.400 mGy/Gy 0.174 0.007 68 mm−1 0.004 10 mm−1
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F I G . 8 . In (a) the measured and model‐predicted ﬁeld length dependence of patient scatter. Furthermore, the ﬁt of the ﬁeld width
dependence. In (b) the measured and model‐predicted dose along a line parallel to the central ﬁeld axis 15 cm from the ﬁeld edge
(R‐dependence 16).
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F I G . 9 . Collimator scatter and head leakage for two nominal X‐ray
energies along the MPAX for a constant patient thickness of 10 cm.
For 15 MV, collimator scatter is shown for a static IMRT and a
3DCRT ﬁeld.
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measurement locations along the MPAX was calculated by a linear
interpolation. To evaluate the exponential decrease with depth,
depth dose curves of the collimator scatter and head leakage were
measured at different distances along the MPAX.
For ﬁxed jaw positions, we noticed a change in collimator scatter
with a changing MLC width opening. To account for this effect, colli-
mator scatter for different MLC width openings (jaws constant at
10 × 10 cm2) was measured at different distances along the MPAX.
With the results, a scaling matrix was calculated which corrected for
the change of collimator scatter with changing MLC width opening. No
such effect was noticed for a variation in the MLC length opening.16
To calculate collimator scatter and head leakage for a treatment,
the dose contributions along the MPAX were scaled with the expo-
nential decrease in depth. To determine the depth, the patient was
assumed to be water equivalent with the exception of the lungs
(ρlungs = 0.25 × ρwater). A more detailed description how the depth in
the patient was calculated for each treatment ﬁeld can be found in
Hauri et al.16
In Fig. 9, we see collimator scatter and head leakage per
100 MUs along the MPAX in the center of the RW3 phantom. Colli-
mator scatter is shown for a ﬁxed jaw ﬁeld size of 10 × 10 cm2 in
combination with an MLC ﬁeld size of 9 × 10 cm2, representing a
3DCRT ﬁeld, and for an MLC ﬁeld size of 3 × 10 cm2, representing
an IMRT ﬁeld. The ﬁeld sizes were similar to the ﬁeld sizes of the
3DCRT and IMRT treatments measured in the presented work. For
calculation of the dose, the IMRT treatment with dynamic MLC was
approximated by static ﬁelds. For the 3DCRT ﬁelds, the ratio of colli-
mator scatter between 15 and 6 MV decreased from 1.5 to 0.88 for
increasing distance to the isocenter. This is in agreement with other
publications, reporting increased collimator scatter close to the ﬁeld
edge with increasing energy.1
Close to the ﬁeld edge, collimator scatter of the 15 MV IMRT
ﬁeld was 0.7 times smaller than the 15 MV 3DCRT ﬁeld. We believe
that this difference was caused by the shielding effect of the MLC
for photons of the primary beam scattered in the gantry head. The
ratio of collimator scatter between the IMRT and the 3DCRT ﬁeld
rose to 1.3 (25 cm from isocenter) with increasing distance to the
ﬁeld edge. As a potential explanation serves the additional photon
scatter from the MLC, which outweighed the shielding effect of the
MLC. At distances ≥40 cm from the isocenter, there was no differ-
ence in collimator scatter per MU between the 3DCRT and IMRT
ﬁeld.
Along the MPAX, head leakage for 6 MV was around 1.6 times
higher than head leakage for 15 MV. For both nominal X‐ray energies,
head leakage showed the same increase for increasing distance to the
isocenter. A possible explanation could be the change in photon
attenuation for different paths through the gantry head's shielding.
In Table 4, we see the measured attenuation coefﬁcient for colli-
mator scatter and head leakage. In contrast to the expectation, the
attenuation of the scatter contribution was higher for 15 MV than
for 6 MV. The attenuation for collimator scatter was calculated using
a straight line connecting the rear jaw and the point of interest in
the patient. For head leakage, the attenuation was calculated using a
straight line connecting the X‐ray producing target with the point of
interest located in the patient.
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